Author

Huirong Pan

Observed names: Hui-Rong Pan, Hui-rong Pan

Institutions: Wenzhou Medical University, Affiliated Eye Hospital of Wenzhou Medical College

Observed institutions: Xiamen University, Wenzhou Medical University, Affiliated Eye Hospital of Wenzhou Medical College, Jiangsu Provincial Center for Disease Control and Prevention, Xiamen Innovax Biotech Co., Ltd. (China), State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Huazhong University of Science and Technology

OpenAlex ID: A5010898734

Long-Term Efficacy of a Hepatitis E Vaccine

2015 · Jun Zhang, Xue-Feng Zhang, et al. · New England Journal of Medicine · 378

PDF

Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial

2019 · You-Lin Qiao, Ting Wu, et al. · JNCI Journal of the National Cancer Institute · 170

PDF

Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial

2022 · Fang-Hui Zhao, Ting Wu, et al. · The Lancet Infectious Diseases · 93

Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin®

2014 · Xiao Zhang, Minxi Wei, et al. · Vaccine · 93

Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial

2024 · Shoujie Huang, Xuefeng Zhang, et al. · The Lancet · 78

2021 · Chun-Lan Zhuang, Zhi-Jie Lin, et al. · Emerging Microbes & Infections · 61

PDF

Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women

2019 · Yue-Mei Hu, Meng Guo, et al. · Science China Life Sciences · 53

PDF

Characterization of an Escherichia coli -derived human papillomavirus type 16 and 18 bivalent vaccine

2017 · Ying Gu, Minxi Wei, et al. · Vaccine · 51

Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18–26 years in China: a randomised blinded clinical trial

2023 · Feng-Cai Zhu, Guo-Hua Zhong, et al. · The Lancet Infectious Diseases · 45

Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination

2014 · Hui Zhao, Zhi-Jie Lin, et al. · Human Vaccines & Immunotherapeutics · 37

PDF

Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years

2019 · Xu-ya Yu, Zhi-ping Chen, et al. · Vaccine · 36

N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro

2018 · Minxi Wei, Daning Wang, et al. · Emerging Microbes & Infections · 30

Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial

2015 · Ting Wu, Yue-Mei Hu, et al. · Vaccine · 30

Safety of hepatitis E vaccination for pregnancy: a post-hoc analysis of a randomized, double-blind, controlled phase 3 clinical trial

2023 · Guohua Zhong, Chunlan Zhuang, et al. · Emerging Microbes & Infections · 26

Naturally acquired HPV antibodies against subsequent homotypic infection: A large-scale prospective cohort study

2021 · Xingmei Yao, Wen Chen, et al. · The Lancet Regional Health - Western Pacific · 24

PDF

Hepatitis E virus capsid protein assembles in 4 M urea in the presence of salts

2012 · Chunyan Yang, Huirong Pan, et al. · Protein Science · 22

Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages

2020 · Qi Chen, Hui Zhao, et al. · Vaccine · 14

Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial

2023 · Kai Chu, Zhao-Feng Bi, et al. · The Lancet Regional Health - Western Pacific · 13

PDF

Altered antigenicity and immunogenicity of human papillomavirus virus-like particles in the presence of thimerosal

2019 · Siyi Chen, Xiaofen Huang, et al. · European Journal of Pharmaceutics and Biopharmaceutics · 13

Demonstration of real-time and accelerated stability of hepatitis E vaccine with a combination of different physicochemical and immunochemical methods

2019 · Xiaochen Yin, Xin Wang, et al. · Journal of Pharmaceutical and Biomedical Analysis · 11

Bacterially expressed human papillomavirus type 6 and 11 bivalent vaccine: Characterization, antigenicity and immunogenicity

2017 · Huirong Pan, Zhihai Li, et al. · Vaccine · 11

Safety and immunogenicity of an Escherichia coli -produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial

2022 · Zhao-Jun Mo, Zhao-Feng Bi, et al. · Human Vaccines & Immunotherapeutics · 10

PDF

Multifaceted characterization of recombinant protein-based vaccines: An immunochemical toolbox for epitope-specific analyses of the hepatitis E vaccine

2018 · Xin Wang, Min Li, et al. · Vaccine · 8

Capsid destabilization and epitope alterations of human papillomavirus 18 in the presence of thimerosal

2020 · Xiaofen Huang, Yike Li, et al. · Journal of Pharmaceutical Analysis · 6

PDF

Immunogenicity of an Escherichia coli -produced bivalent human papillomavirus vaccine under different vaccination intervals

2020 · Xiao-Juan Yu, Juan Li, et al. · Human Vaccines & Immunotherapeutics · 6

PDF

Works count: 49

Citation count: 1,360

H-index: 16

I10-index: 23